Stephen J.LurieMD, PhD, Senior Editor
Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002American Medical Association
To the Editor: Although the WHI investigators first became aware of the possibility of cardiovascular harmful effects of the progestin-estrogen combination in late 1999, the data and safety monitoring board (DSMB) did not stop the trial then.1 This decision seems questionable in light of other important double-blind placebo-controlled trials published in 1998-1999, such as HERS,2 PEPI mammography results,3 and SPAF,4 all of which found evidence of potential harmful cardiovascular and premalignant effects of combined HRT.
Lev I, Lahad A, Karni A. Risks of Postmenopausal Hormone Replacement. JAMA. 2002;288(22):2821. doi:10.1001/jama.288.22.2821-JLT1211-1-7